Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eli Lilly & Co. (LLY) Raises Quarterly Dividend 15.3% to $0.98; 1.6% Yield
December 13, 2021 3:36 PM ESTEli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $0.98 per share, or $3.92 annualized. This is a 15.3% increase from the prior dividend of $0.85.
The dividend will be payable on March 10, 2022, to stockholders of record on February 15, 2022, with an ex-dividend date of February 14,... More
Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst
December 13, 2021 9:59 AM ESTEarlier today, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development... More
Pre-Open Stock Movers 12/13: (ARNA) (FHTX) (HOG) Higher; (NISN) (TXMD) (AMPE) Lower (more...)
December 13, 2021 9:21 AM ESTPre-Open Stock Movers
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 86.7% HIGHER; Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7... More
Foghorn Therapeutics Inc. (FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (LLY)
December 13, 2021 6:15 AM ESTFoghorn Therapeutics Inc. (NASDAQ: FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (NYSE: LLY)
... MoreEli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform
December 13, 2021 6:03 AM ESTLoxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn's proprietary Gene Traffic Control platform.
Under the terms of the agreement, Foghorn will receive upfront... More
